State Street’s Rubius Therapeutics, Inc RUBY Stock Holding History

State Street’s Portfolio RUBY Stock Details RUBY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-147,789	Closed	-$25.4K	–	4873
2022 Q4	$25.4K	Hold	147,789	–	–	﹤0.01%	4693
2022 Q3	$64K	Hold	147,789	–	–	﹤0.01%	4604
2022 Q2	$126K	Sell	147,789 -846,338	-85%	-$1.42M	﹤0.01%	4414
2022 Q1	$5.48M	Sell	994,127 -1,176,410	-54%	-$7.47M	﹤0.01%	3134
2021 Q4	$21M	Sell	2,170,537 -186,848	-8%	-$2.59M	﹤0.01%	2446
2021 Q3	$42.1M	Sell	2,357,385 -82,910	-3%	-$1.8M	﹤0.01%	1933
2021 Q2	$59.6M	Buy	2,440,295 +1,798,409	+280%	+$45M	﹤0.01%	1713
2021 Q1	$17M	Sell	641,886 -24,854	-4%	-$363K	﹤0.01%	2468
2020 Q4	$5.06M	Sell	666,740 -7,721	-1%	-$45.9K	﹤0.01%	2952
2020 Q3	$3.38M	Sell	674,461 -7,563	-1%	-$40.1K	﹤0.01%	2979
2020 Q2	$4.08M	Buy	682,024 +25,469	+4%	+$150K	﹤0.01%	2857
2020 Q1	$2.92M	Sell	656,555 -6,723	-1%	-$49.9K	﹤0.01%	2884
2019 Q4	$6.3M	Buy	663,278 +38,060	+6%	+$368K	﹤0.01%	2742
2019 Q3	$4.91M	Buy	625,218 +17,801	+3%	+$207K	﹤0.01%	2798
2019 Q2	$9.55M	Buy	607,417 +95,959	+19%	+$1.55M	﹤0.01%	2537
2019 Q1	$9.26M	Buy	511,458 +326,913	+177%	+$5.02M	﹤0.01%	2507
2018 Q4	$2.97M	Buy	184,545 +28,875	+19%	+$526K	﹤0.01%	2957
2018 Q3	$3.74M	Buy	+155,670	New	+$3.56M	﹤0.01%	2995

Other funds holding RUBY

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

SOMRS

State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BBA

Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.28B AUM 38.1% 1-Year Est. Return

CGL

Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return

State Street's RUBY Position: Q1 2023 in Review

State Street sold out of Rubius Therapeutics, Inc (RUBY) in Q1 2023, closing a stake of 147,789 shares — an estimated $25.4K sold.

State Street first reported a position in RUBY in Q3 2018 and held it in 18 quarters. The position peaked at $59.6M in Q2 2021. 7 funds tracked by Wall St. Rank hold RUBY as of Q1 2023.

State Street reported no remaining Rubius Therapeutics, Inc position as of Q1 2023 after selling out during the quarter.
State Street sold 147,789 Rubius Therapeutics, Inc shares in Q1 2023, an estimated $25.4K.
State Street first reported a position in Rubius Therapeutics, Inc in Q3 2018 and held it in 18 quarters.
State Street's Rubius Therapeutics, Inc position peaked at $59.6M in Q2 2021.
7 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q1 2023.

Based on State Street's 13F filing for Q1 2023, filed 15 May 2023.